The future of immuno-oncology discussion with Agenus at ESMO GI 2024

Agenus shared a post on LinkedIn:

“Are you a physician attending ESMO GI 24?

Join us in Munich from June 26-29 to discuss the future of immuno-oncology with our Medical Affairs team.

To Schedule a meeting, click here.”

Source: Agenus/LinkedIn

ESMO GI 2024 will take place in Munich, Germany, from 26 to 29 June 2024, as well as online, through a virtual platform.

Agenus (formerly Antigenics Inc.) is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology. The company is involved in developing checkpoint modulators (CPMs) and patient-specific anti-cancer vaccines. Agenus was founded in 1994 by Garo H. Armen and Pramod K. Srivastava. Agenus became a public company in February 2000 on the NASDAQ exchange.

Other posts from Agenus on OncoDaily.